Q-Suite™ Holmium-166 SIRT treatment planning software receives CE-mark approval

Published by admin on

DEVENTER, Jun. 8 2020 – Quirem Medical announced today it received CE-mark approval for the latest version of Q-Suite™, dosimetry software for holmium-166 SIRT. Q-Suite™ is the only dosimetry software solution tailored to treatment planning and treatment evaluation of Holmium-166 Selective Internal Radiation Therapy (SIRT). In combination with the work-up product QuiremScout® and treatment product QuiremSpheres®, the software solution facilitates improved patient selection and treatment planning to further optimize SIRT outcomes.

The new CE-mark for Q-Suite™ adds SIRT treatment planning functionality to the already available treatment evaluation features. Founder and CEO of Quirem Medical, Jan Sigger comments: “The treatment planning functionality in Q-Suite completes our integrated holmium-SIRT solution, built around QuiremSpheres®, QuiremScout® and Q-Suite™. This integrated solution will give physicians the tools to further personalize SIRT towards the individual needs of each patient”

Treatment planning with Q-Suite™ includes calculation of the required QuiremSpheres® treatment activity, prediction of lung dose based on a QuiremScout® or Tc-99m MAA pre-scan and performing a pre-treatment dose simulation. Treatment evaluation with Q-Suite™ allows for dosimetry after QuiremSpheres® SIRT using MR or SPECT-CT images.

Gerrit van de Maat, software development lead at Quirem Medical comments: “Q-Suite™ leverages the unique imaging properties of holmium-166 microspheres for treatment planning and evaluation. We are pleased that we could include planning functionality to support physicians during the holmium-166 SIRT work-up phase. While extending the functionality, we ensured that Q-Suite™ remains simple and intuitive to use in daily clinical practice.

 

About Quirem Medical B.V.

Quirem Medical is an emerging medical device company with a mission to develop the next generation microspheres for selective internal radiotherapy (SIRT) of liver malignancies. Quirem Medical BV is a spin-off company of the University Medical Center Utrecht (UMCU) and commercializes, manufactures and distributes a new type of SIRT microspheres based on the isotope holmium, named QuiremSpheres®. QuiremSpheres® and QuiremScout® have received CE-mark approval in April 2015 and December 2018 respectively and are currently being used by numerous centers in Europe and Turkey.

Categories: News